Greenleaf Peter has made a significant move by acquiring 160,000 stock options in Altimmune, Inc. This acquisition, reported in a recent SEC filing, is noteworthy as it reflects a strategic investment in the pharmaceutical preparations sector.

The options were acquired at an exercise price of $2.02 each, with the transaction dated November 2, 2026. According to the filing, the shares underlying the options will vest in substantially equal monthly installments over the next three years, contingent upon Greenleaf's continued service.

Background

Greenleaf Peter is a reporting owner associated with Altimmune, Inc. The company is classified under the SIC code for pharmaceutical preparations and is traded under the ticker symbol ALT. Altimmune, Inc. is known for its innovative approaches in the life sciences sector, focusing on developing treatments for various diseases.

What the Filing Says

"The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following November 2, 2026, subject to the reporting person's continued service through the applicable vesting date."

Impact

This acquisition may affect Altimmune's stock performance and investor sentiment, as it indicates confidence from a key stakeholder. The pharmaceutical industry, particularly companies involved in innovative drug development, may also view this as a positive sign of investment in future growth.

What's Next

The filing does not say what happens next.